Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

A rare gain of function *HCN4* gene mutation is responsible for inappropriate sinus tachycardia in a Spanish family

Anabel Cámara-Checa,^{1,2*} Francesca Perin,^{3,4*} Marcos Rubio-Alarcón,^{1,2} María Dago,^{1,2} Teresa Crespo-García,^{1,2} Josu Rapún,^{1,2} María Marín,² Jorge Cebrián,^{1,2} Francisco Bermúdez-Jiménez,^{3,4,5}Lorenzo Monserrat,^{2,6} Juan Tamargo,¹ Ricardo Caballero,^{1,2#} Juan Jiménez-Jáimez,^{3,4} Eva Delpón.^{1,2#}

- Department of Pharmacology and Toxicology. School of Medicine. Universidad Complutense de
 Madrid. Instituto de Investigación Gregorio Marañón. 28040-Madrid, Spain.
- ²CIBERCV. Instituto de Salud Carlos III. Spain.
- ³Department of Pediatric Cardiology. Virgen de las Nieves University Hospital. 18014-Granada,
- 13 Spain.

1

2

4

5

6

7 8

17

19

20

22 23

- ⁴Instituto de Investigacion Biosanitaria de Granada IBS. 18014-Granada, Spain
- 15 ⁵Centro Nacional de Investigaciones Cardiovasculares (CNIC). 28029-Madrid, Spain
- 16 ⁶Health in Code SL. 15008-A Coruña, Spain.
- 18 *Co-senior authors
 - *Both authors contributed equally
- 21 Short title: p.V240M HCN4 and inappropriate sinus tachycardia
- 24 Corresponding author:
- 25 Ricardo Caballero
- 26 Department of Pharmacology and Toxicology.
- 27 School of Medicine
- 28 Universidad Complutense de Madrid
- 29 Ramón y Cajal Square
- 30 28040-Madrid. SPAIN
- 31 rcaballero@ucm.es

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

ABSTRACT

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

Background. In a family with inappropriate sinus tachycardia (IST) we identified a novel mutation (p.V240M) of the hyperpolarization-activated cyclic nucleotide-gated type 4 (HCN4) channel, which contributes to the pacemaker current (If) in human sinoatrial node cells. Here we clinically study the family and functionally analyze the p.V240M variant. Methods. Macroscopic (I_{HCN4}) and single-channel currents were recorded using patch-clamp in cells expressing human native (WT) and/or p.V240M HCN4 channels. Results. All p.V240M mutation carriers exhibited IST (mean heart rate 113[7] bpm, n=9), that in adults, was accompanied by cardiomyopathy. I_{HCN4} generated by p.V240M channels either alone or in combination with WT was significantly greater than that generated by WT channels. The variant, which lies in the N-terminal HCN domain, increased single-channel conductance and opening frequency and probability of HCN4 channels. Conversely, it did not modify channel sensitivity for cAMP and ivabradine or the level of expression at the membrane. Treatment with ivabradine based on functional data reversed the IST and the cardiomyopathy of the carriers. Conclusions. The p.V240M gain-of-function variant increases If during diastole, which explains the IST of the carriers. The results demonstrate the importance of the unique HCN domain in HCN4 which stabilizes the channels in the closed state. Funding. Ministerio de Ciencia e Innovación (PID2020-118694RB-I00); Comunidad Autónoma de Madrid (P2022/BMD-7229), European Structural and Investment Funds); and Instituto de Salud Carlos III (CIBERCV; CB16/11/00303).

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

INTRODUCTION

54

55

56

57

58

59

60 61

62

63

64

65

66

67

68 69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

Inappropriate sinus tachycardia (IST) is a clinical syndrome with an estimated prevalence of around 1% (more frequent in young women) and a significant impact on the quality of life of the affected individuals (Baruscotti et al., 2016; Olshansky and Sullivan, 2019). IST is defined by a sinus heart rate (HR) inexplicably higher than 100 beats per min (bpm) at rest or higher than 90 bpm on average over 24 hours. The pathophysiology of IST is still not fully understood as the processes involved in pacemaking and its modulation are extremely complex (Baruscotti et al., 2016; Olshansky and Sullivan, 2019). Any participating mechanisms can affect the HR and result in this syndrome, including an intrinsic increase in sinoatrial node automaticity (Baruscotti et al., 2016), excess sympathetic tone and reduced cardiovagal tone (Nwazue et al., 2014), and circulating anti-beta-adrenergic receptor antibodies (Chiale et al., 2006), among others. The hyperpolarization-activated cyclic nucleotide-gated (HCN) channel family comprises 4 members (HCN1-4) and have the peculiarity that they are activated by hyperpolarization rather than depolarization (Biel et al., 2009). These channels are expressed in the heart and in the central and peripheral nervous systems and exhibit a unique ion selectivity since they allow the passage of a depolarizing mixed Na⁺ and K⁺ current (Biel et al., 2009). In the heart, the current is known as pacemaker or funny current (I_f) (because of its quite unusual biophysical profile) and has a key role in controlling the rhythmic activity in sinoatrial node cells (Biel et al., 2009; DiFrancesco, 2010; Hennis et al., 2022; Rivolta et al., 2020). Neuronal current is generally designated as hyperpolarization-activated current or In and contributes to controlling neuronal excitability. HCN channels contain a cyclic nucleotide-binding domain (CNBD) in the carboxyl terminus connected to the pore-forming S6 transmembrane segment via the C-linker (Lee and MacKinnon, 2017). cAMP or cGMP binding to the CNBD induces a rightward shift of the voltage dependence of HCN4 channel activation (DiFrancesco and Tortora, 1991; Wainger et al., 2001), thus increasing the current. Furthermore, all HCN channel isoforms contain an N-terminal domain (HCND) that, in HCN1 and HCN2 has been demonstrated to stabilize the closed pore in the setting of a depolarized voltage sensor and that physically interacts with the CNBD and the voltage-sensor domain (VSD) (Lee and MacKinnon, 2017; Porro et al., 2019). HCN family members differ in their sensitivity to cAMP, opening kinetics, and preferential tissue distribution (Biel et al., 2009). It is generally accepted that in all mammalian species studied so far, HCN4 was found to be the main HCN channel isoform in the sinoatrial node although HCN1 and HCN2 isoforms are also present (Baruscotti et al., 2016, 2005; Shi et al., 1999). However, there are data

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

86

87

88

89

90

91

92 93

94

95

96

97

98

99

100

101

102

suggesting that HCN1 is the predominant isoform expressed in the human sinoatrial node (Li et al., 2021, 2015). In a large Spanish family with IST, we identified a novel heterozygous mutation (p.V240M) within the HCND of HCN4 channels. Understanding the pathophysiology of IST is crucial to find a treatment for this debilitating condition. For its part, the gating properties of HCN4 channels and their role in cardiac pacemaking are currently not fully understood. Thus, we decided to clinically study all family members and functionally analyze the p.V240M HCN4 mutation through biochemical and electrophysiological approaches even at the single-channel level. Our results demonstrated that p.V240M is the first naturally occurring HCND gain-of-function mutation causing an increased inward current flow during diastole accounting for the fasterthan-normal heart rate of all carriers, that was reversed with treatment with ivabradine, a selective HCN channel blocker (Baruscotti et al., 2005). Moreover, at the molecular level our findings demonstrate the critical importance of the HCND in the gating o Our results strengthen the importance of genetic and functional studies in families carrying mutations with uncertain significance since they allow the implementation of a personalized treatment f HCN4 channels. and help to the understanding of the mechanisms controlling human cardiac electrophysiological properties.

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

RESULTS

Clinical and genetic characteristics of the patients

The proband (III.3 in Figure 1A) is a female in her 30's (31-35), with a mean 24-h HR of 106[17] bpm (Table 1 and Figure 1B). After a thorough evaluation, no reversible causes of sinus tachycardia were found (i.e., hyperthyroidism, anemia, diabetes, orthostatic hypotension, infections, and drug abuse), thus establishing the diagnosis of IST. The echocardiogram and cardiac magnetic resonance (CMR) showed mild systolic dysfunction [left ventricular ejection fraction (LVEF)=43%], and no gadolinium enhancement. No signs of left ventricular noncompaction or hypertrabeculation were found. Her resting HR and electrocardiographic (ECG, in at least three different recordings) and cardiac structural parameters are described in Table 2. Clinical evaluation of her relatives revealed that her father, two siblings, two sons, and three nephews also fulfilled diagnostic criteria of IST, with a mean resting HR of 113[7] bpm (Table 1 and Figure 1).




Figure 1. A family with inappropriate sinus tachycardia. (**A**) Pedigree of the IST proband's family. The arrow indicates the proband (III.3), circles and squares represent females and males, respectively. (**B**) Twelve-lead ECGs of II.1, III.3, and IV.9 family members (paper speed 25 mm/s).

Six more relatives were also clinically studied and none of them was diagnosed with IST (Table 1). No significant electrocardiographic or structural findings were detected in any of the IST patients (Table 2). However, all adults with IST (5 out of 9) had reduced LVEF without gadolinium enhancement, whereas children did not have cardiac dysfunction (Table 1 and Figure 1). As expected, the HR of children was higher than that of adults (mean 24-h HR: 115.2[5.3] vs. 102.7[2.1] bpm, P<0.05, n≥4). Patients IV.4 and IV.8 were diagnosed with fetal tachycardia with

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

HR at 160-170 bpm at birth (>98 percentile). The proband's aunt (II.3) had died after heart transplant due to a congenital heart defect.

These data suggested that in this family there was a genetic component responsible for the IST. Next-generation sequencing (Table Supplement File 1) of the proband identified the pathogenic (according to the guidelines for the interpretation of variants, Table 3 and Methods) heterozygous 15,73659894,C,T (NM_005477.3:c.718G>A) variant in *HCN4* gene encoding p.V240M HCN4 (Figure 2A). The mutated residue is highly conserved among different species and lays in the HCND of the protein (Figure 2 B-D).




Figure 2. The V240 residue is highly conserved and lays in the HCND of the protein. (**A**) DNA sequence chromatogram depicting the heterozygous *HCN4* variation (15,73659894,C,T; c.718G>A) in the proband. (**B**) Schematic diagram of human HCN4 channel highlighting some key domains and the approximate location of the p.V240M variant. (**C** and **D**) Sequence alignment of the region surrounding the V240 residue in HCN4 of several species (**C**) or in the four channels of the HCN family (**D**). The boxes in panels C and D highlight the conservation of this residue.

The p.V240M variant has been previously annotated with an allele frequency of 0.000003982 (https://gnomad.broadinstitute.org, accession date: 11/21/2022) since it was detected on a single allele in a south Asian subject. Cascade screening demonstrated the genotype-phenotype co-segregation of the *HCN4* variant (Figure 1A). All carriers except II.1, who refused any

treatment, were initially treated with ivabradine alone (7.5 mg BID for adults and 5 mg BID for the youngest carrier) with a significant response in terms of mean 24-h HR decrease (94[7] vs. 109[7.9], P<0.05) and improvement in symptoms and quality of life (Table 1). Three adult patients had their ivabradine dose reduced (5 mg BID) since they experienced mild weakness and dizziness, which are frequently associated with the use of this drug. Bisoprolol (5 mg BID) was added to them to achieve a better HR control (from 91[1.5] before to 84[5] after bisoprolol).

Macroscopic current analysis

To test whether the p.V240M HCN4 mutation underlies the IST in this family we functionally analyzed this variant. Figure 3A shows macroscopic HCN4 current (I_{HCN4}) traces generated in three different CHO cells transfected with WT, p.V240M, and the combination of WT and p.V240M HCN4 channels (0.5:0.5 ratio). I_{HCN4} comprises two components (inset in Figure 3A): the minor instantaneous (I_{INS}) and the major slowly developing steady-state current (I_{SS}), whose amplitude progressively increased at more negative potentials (Biel et al., 2009; Mistrík et al., 2006).




Figure 3. Macroscopic currents generated by WT and p.V240M HCN4 channels. (**A** and **B**) I_{HCN4} traces (**A**) and density–voltage relationships (**B**) generated in CHO cells transiently expressing WT, p.V240M, and WT+p.V240M HCN4 channels by applying the protocol depicted at the top. The inset in A shows the minor instantaneous (I_{INS}) and the major slowly developing steady-state HCN4 current (I_{SS}) and the inset in B, shows the data at potentials positive to


Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

-90 mV in an expanded scale. (**C**) Normalized tail current densities generated by WT, p.V240M, and WT+p.V240M channels by applying 1-second pulses to −140 mV were plotted against the membrane potential of the test pulse. Continuous lines represent the Boltzmann fit to the data. (**D**) Fully activated I_{HCN4} density–voltage relationships generated by WT, p.V240M, and WT+p.V240M channels. Continuous lines represent the linear regression to the data. In **B-D**, each point represents the mean±SEM of ≥15 experiments/cells (biological replicates) from ≥3 dishes. In B, *P<0.05 vs. HCN4 WT. #P<0.05 vs. HCN4 WT and P<0.05 vs. p.V240M. Two-way ANOVA and Multiple t-test.

Figure 3-source data 1 of panels B, C, and D.

I_{HCN4} generated by p.V240M channels (measured at the end of the pulses) was significantly greater than that generated by WT channels (Figure 3A and 3B) in a wide range of membrane potentials that includes physiological membrane potentials (-1.2±0.2 *vs.* -8.6±2.6 pA/pF at -60 mV; P<0.05, n=19) (Table 4). Interestingly, densities of I_{HCN4} generated by the cotransfection of WT and p.V240M channels were also significantly greater than those of WT channels (Figure 3A and 3B and Table 4). Figure 3C shows that the p.V240M variant either alone or in combination with WT channels, significantly and markedly shifted the midpoint (Vh) of the activation curve to more depolarized membrane potentials as assessed by Boltzmann fits (Table 4).

Activation time constant (τ_{act}) at -160 mV averaged 509±40, 354±42, and 438±40 ms for I_{HCN4} generated by WT, p.V240M, or WT+p.V240M HCN4 channels, respectively (Figure 4). Thus, the p.V240M mutation either alone or in combination with WT channels, significantly accelerated the activation of I_{HCN4} (P=0.026, n≥17).



Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

Figure 4. p.V240M HCN4 modifies the time dependence of I_{HCN4} activation. (A) Mean time constant of activation (τ_{act}) yielded by the fit of a monoexponential function to the activating phase of HCN4 current (I_{HCN4}) traces elicited by pulses to -160 mV in cells expressing WT, p.V240M or WT+p.V240M channels. Each bar represents the mean±SEM of n experiments and each dot represents one experiment. (B) I_{HCN4} traces recorded by applying the protocol shown at the top to measure deactivation kinetics consisting of two 3-s pulses from -40 to -120 mV that were applied at increasing coupling intervals (1-6 s). For each coupling interval, we measured the instantaneous current (ΔI_{INS}) and the steady-state current (I_{ISS}) elicited at the beginning and at the end, respectively, of the second pulse to -120 mV. (C) Mean $\Delta I_{INS}/I_{ISS}$ measured at each coupling interval for I_{HCN4} recorded in cells expressing WT, p.V240M or WT+p.V240M channels. A monoexponential function was fitted to the data to obtain the time constant of deactivation (τ_{deact}). Each point was the mean±SEM of \geq 7 experiments (biological replicates). In A and C, *P<0.05 vs WT. Two-way ANOVA and multiple t-test. An F-test was performed to determine the statistically significance of the differences between activation time constants obtained in E.

Figure 4-source data 1 of panels A and C.

Channel deactivation properties were analyzed using a double pulse protocol (Schweizer et al., 2010). Figure 4C shows that deactivation of p.V240M channels alone, but not in combination with WT, was significantly slower than that of WT channels (P<0.05, n≥7) and, as a consequence, the ratio of p.V240M channels that remained activated is greater for all the interpulse intervals (Table 4).

Effects of cAMP on p.V240M HCN4 channels

Interestingly, effects produced by the p.V240M variant are quite similar to those produced by cAMP (DiFrancesco and Tortora, 1991) and thus, we hypothesized that the mutation increases I_{HCN4} by augmenting HCN4 channel affinity for cAMP. Since HCN4 activation is not affected by cAMP when channels are expressed in CHO cells (Peters et al., 2020), we tested our hypothesis in HEK293 cells that were exposed to a saturating cAMP concentration (10 μ M) in the whole-cell pipette solution.





Figure 5. Effects of cAMP on the voltage dependence of I_{HCN4} activation. (A and B) Voltage dependence of I_{HCN4} generated by WT (A) and p.V240M (B) channels expressed in HEK293 cells in the presence or absence of 10 μM cAMP. Tail current densities generated by applying 1-s pulses to −140 mV were normalized and plotted against the membrane potential of the test pulse. Continuous lines represent the Boltzmann fit to the data. Each point represents the mean±SEM of ≥6 experiments/cells (biological replicates) from ≥3 dishes.

Figure 5-source data 1 of panels A and B.

As expected, cAMP significantly shifted the activation curve of WT HCN4 channels toward depolarizing potentials (Figure 5A). In HEK293 cells the Vh of p.V240M HCN4 channel activation was also significantly more depolarized than that of WT channels (-111.3 \pm 3.8 mV, n \geq 8, P<0.05). Importantly, voltage-dependent activation of p.V240M channels was significantly shifted in the presence of cAMP (-97.1 \pm 5.2 mV, n \geq 6, P<0.05) (Figure 5B).

Effects of the p.V240M HCN4 mutation on the membrane expression

To analyze whether an increase of the expression of p.V240M HCN4 channels at the plasma membrane accounted for the I_{HCN4} increase, we conducted a cell surface biotinylation assay (Figure 6) measuring the levels of expression of total HCN4 protein (inputs) and membrane fraction (biotinylated) by Western blot (WB) (Figure 6A). Figure 6B shows the densitometry of the relative surface expression of WT and p.V240M HCN4 subunits and demonstrates that there were not significant differences in the expression of mutated and WT channels (P>0.05, n=5).






Figure 6. Membrane expression of WT and p.V240M HCN4 channels. Representative WB images (A) and densitometric analyses (B) of biotinylation assays showing the total (input) or surface (membrane) expression of HCN4 in cells expressing WT or p.V240M channels. The cytosolic protein ezrin was used as a negative control. In B, each dot represents 1 experiment and each bar the mean±SEM of n experiments (biological replicates). Unpaired Student t-test.

Figure 6-source data 1 of panel A.

234

235 236

237 238

239

240

241

242 243 244

245

246

247

Figure 6-source data 2 of panel B.

Single-channel properties of p.V240M HCN4 channels

Figure 7 shows representative single-channel traces recorded in CHO cells at -90 mV in the absence (control, top panels) or the presence (bottom panels) of ivabradine (5 μM), a selective If inhibitor (Baruscotti et al., 2005), using the cell-attached configuration.

249

250 251

252

253

254

255

256

257

258

259

260

261




Figure 7. Single-channel recordings generated by WT and p.V240M HCN4 channels. Single channel recordings obtained by applying 3-s pulses from 0 to -90 mV in cells expressing or not (A) WT (B) or p.V240M (C) HCN4 channels in the absence and presence (D-F) of ivabradine 5 μM.

In all experiments we confirmed that ivabradine perfusion completely inhibited the unitary HCN4 current (i_{HCN4}). Importantly, the p.V240M mutation did not modify the HCN4 channel sensitivity to ivabradine (Figure 8). No single-channel recordings were obtained in nontransfected cells since they do not express endogenous HCN4 channels (Figure 7A and 7D).




Figure 8. p.V240M does not modify HCN4 channel sensitivity to ivabradine. Concentration-response curves for ivabradine-induced inhibition of the I_{HCN4} recorded at -140 mV in cells expressing WT or p.V240M HCN4 channels. Solid lines represent the fit of a Hill equation to the data; the nH was fixed to unity, and bottom and top values to 0 and

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

100%, respectively. Each point was the mean±SEM of at least 3 experiments/cells (biological replicates). Statistical comparison between both curves was analyzed by an F-test (P=0.51).

Figure 8-source data 1.

 i_{HCN4} generated by WT channels (Figure 7B) was characterized by spontaneous openings followed by periods of channel closure yielding mean f_0 and P_0 values of 5.2±1.1 Hz and 0.11±0.02 (n=5), respectively (Figure 9A and 9B and Table 4).




Figure 9. Gating properties of WT and p.V240M HCN4 channels. Mean f_0 (**A**), P_0 (**B**) and open time (**C**) for i_{HCN4} recorded in cells expressing WT or p.V240M HCN4 channels. (**D**) i_{HCN4} amplitude generated by WT and p.V240M channels after applying pulses to -90 mV. (**E**) i_{HCN4} -voltage relationships generated by WT and p.V240M channels. In **A-D** each dot represents 1 experiment/cell and each bar the mean±SEM of n experiments/cells (biological replicates) as indicated in the figure. In **E** each point represents the mean±SEM of ≥4 experiments/cells (biological replicates). *P<0.05 vs. WT. Unpaired Student t-test. An F-test was performed to determine the statistically significance of the differences between conductance values.

Figure 9-source data 1 of panels A-E.

Conversely, i_{HCN4} generated by p.V240M channels was characterized by openings in bursts (Figure 7C). Accordingly, both f_0 and P_0 significantly increased, while the mean open time significantly decreased compared to those of WT channels (P<0.05, n \ge 5) (Figure 9A-9C and Table 4). Moreover, i_{HCN4} amplitude generated by p.V240M channels at -90 mV (Figure 9D) and at all membrane potentials tested was significantly greater than that of WT channels (Figure 9E,

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299 300

301

302

303

304

P<0.05, n=5). Figure 9E shows that single-channel conductance (y) derived from the linear regression of the current-voltage relationships of p.V240M channels was double than that of WT channels (Table 4). Importantly, y here obtained for WT channels (16.3±2.7 pS) is in agreement with that previously reported for HCN4 channels (Brandt et al., 2009; Michels et al., 2005).

Gating kinetics was characterized by means of dwell-time histograms (Methods). Both close and open dwell-time histograms were fitted by monoexponential functions (Figure 10) yielding τ_{CLOSED} and τ_{OPEN} of 68.1 and 17.3 ms, respectively for WT channels. The mutation significantly reduced both the τ_{CLOSED} and the τ_{OPEN} (P<0.05) (Table 4 and Figure 10).




Figure 10. p.V240M modifies single channel gating kinetics. (A-D) Closed- (A and C) and open (B and D) dwell-time histograms for currents recorded in cells expressing HCN4 WT (A and B) or HCN4 p.V240M (C and D) (bin width= 25 ms). Continuous lines represent the fit of a monoexponential function to the data, which yielded the indicated closed (TCLOSED) and open (TOPEN) time constants. Histograms were obtained by pooling data from 5 (WT) and 10 (p.V240M) experiments (biological replicates). *P<0.05 vs WT (F-test).

Figure 10-source data 1 of panels A-D.

Mathematical model of human sinoatrial action potentials

Figure 11A shows human sinoatrial APs obtained when running the Fabbri-Fantini-Wilders-Severi mathematical model (Fabbri et al., 2017) considering the If generated by WT HCN4 channels. AP characteristics are described in Table 5. Spontaneous firing frequency of the AP averaged 73.8 bpm and it was almost doubled (146.3 bpm) when APs were modeled considering

305

306

307

308

309


310

311 312

313

the I_f generated by p.V240M channels (Figure 11A). The acceleration of the pacemaker frequency is consequence of the huge increase in the I_f density produced by the mutation (Figure 11B). Interestingly, If currents generated when considering the heterozygous presence of p.V240M channels are also greater than those generated by WT channels and the firing frequency (108 bpm) is close to that of the carriers of the mutation.

Mathematical model of the human sinoatrial action potentials






Figure 11. Mathematical model of human sinoatrial node cell action potential. (A and B). APs (A) and If (B) obtained when running the Fabbri-Fantini-Wilders-Severi model under basal conditions (WT; left), or after introducing the experimentally measured I_{HCN4} changes induced by p.V240M alone (center) or together with WT (right).

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

DISCUSSION

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

In this study we identified several members of a family diagnosed with IST carrying a novel gainof-function HCN4 variant. The results of our functional analysis demonstrated that p.V240M variant markedly increases the f_0 and the P_0 and depolarizes the voltage dependence of HCN4 channels activation. Thus, the mutation increases I_{HCN4} by altering the gating without modifying the channel sensitivity for cAMP and ivabradine or the membrane expression. All these effects account for the huge increase of I_{HCN4}, which, in turn, explains the IST of the affected family members who were treated with ivabradine, which reversed IST and tachycardia-induced cardiomyopathy. The p.V240M mutation is, to the best of our knowledge, the second HCN4 gain-of-function mutation described in the literature. The first one was the p.R524Q HCN4 variant, that increases the channel affinity for cAMP and was described in an Italian family with symptomatic sinus tachyarrhythmia (Baruscotti et al., 2017). Conversely, many loss-of-function heterozygous mutations in the HCN4 gene have been associated with sinus bradycardia that can be accompanied, or not, with atrial fibrillation, atrioventricular block, structural diseases such as noncompaction cardiomyopathy, and even QT prolongation (Alonso-Fernández-Gatta et al., 2021; Cambon-Viala et al., 2021; Macri et al., 2014; Milanesi et al., 2006; Nof et al., 2007; Rivolta et al., 2020; Schweizer et al., 2010; Ueda et al., 2004; Verkerk and Wilders, 2015). As mentioned, there has been important controversy regarding the role of HCN4 isoforms in generating human $\mathfrak{l}_{\mathsf{f}}$ and in pacemaking of sinoatrial node. There are reports demonstrating that the predominant HCN isoform at both the protein and RNA levels is HCN1 (Li et al., 2021, 2015). However, only a few data on the literature suggested the contribution of HCN1 variants to HR. One of them is a case report (Yu et al., 2021) showing two rare HCN1 heterozygous variants identified in a young patient with profound sinus bradycardia. The second report identifies a polymorphic HCN1 variant that was associated with HR variability and schizophrenia (Refisch et al., 2021). Conversely, dysfunctional HCN1 channels seem to play an important role in different forms of epilepsy and neuropathic pain (DiFrancesco et al., 2019; He et al., 2019). Our results add further support to the contention that in humans, HCN4 channels critically determine If density in sinoatrial cells, thus regulating HR. The V240 residue is located in the N-terminus, and variants in this domain are less commonly described than in the pore and C-terminal regions of HCN4 channels. The HCND is formed by a stretch of 45 aminoacids directly preceding the S1 transmembrane segment that consists of three α-helices (HCNa, HCNb, and HCNc) (Figure 2) (Lee and MacKinnon, 2017). The V240

residue is actually located in the HCNc α -helix. The HCND could act as a sliding crank that converts the planar rotational movement of the CNBD into a rotational upward displacement of the VSD mechanically coupling thus, the CNBD and the VSD (Porro et al., 2019; Wang et al., 2020). HCND normally keeps the VSD in a position, which is unfavorable for channel opening (Porro et al., 2019). To test the possible molecular mechanism responsible for the gain-of-function effects of p.V240M we have mutated *in silico* a human HCN4 model (PDB:6GYN, Figure 12).




Figure 12. Molecular modeling of WT and p.V240M HCN4 channels. (**A**) Ribbon representation of the cryo-EM structure of human HCN4 (PDB:6GYN). Only two diagonal subunits are shown for clarity. The transmembrane segments (TM) are gray, the HCND is orange, the C-linker is red, the CNBD is blue, and the distal C helix is green. (**B**) Close view of superimposed WT and V240M models (colour coded as in **A**). Sticks representation shows amino acids side-chains from WT (cyan) and V240M (purple). V240 and M240 are shown as spheres. (**C**) Interaction of HCND with the VSD showing the hydrophobic interactions of F229 with I404 and M407 from TM S4 (VSD) and Y258 from the loop connecting HCND to TM S1, and polar contacts of K228 and Y409 in WT (red dashed line) or K228 and N227 in V240M (yellow dashed line). Spheres represent the van der Waals surface occupied by the side chains.

In HCN4 channels the HCND is anchored to the VSD by means of phenylalanine F229, whose aromatic side chain is inserted between transmembrane helices S1 and S4 in a hydrophobic pocket formed by I404 and M407 in S4, and Y258 in S1 (Figure 12B-C). Interestingly, the introduction of the methionine residue at this position remarkably reduced the energy in the most stable p.V240M conformation (–23.49 kcal/mol) compared to WT (–60.18 kcal/mol). Moreover, our molecular modeling demonstrates that the mutation introduces a slight torsion

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

of the aromatic group of F229 and prevents the H-bond between K228 in HCND and Y409 in S4 (Figure 12C). These effects might weaken the interaction between HCND and VSD. Thus, these results suggest that p.V240M mutation limits the inhibitory action of the HCND on the VSD. The latter could explain the marked positive displacement (≈20 mV) of the activation curve of p.V240M channels. Indeed, our results are in accordance with those obtained by Porro et al (Porro et al., 2019) who showed that disrupting the interaction between the HCND and the S4 TM of the VSD produced a depolarizing shift in the voltage dependence of activation. The cAMP-induced movement of the C-linker produced by the binding of cAMP to the CNBD is transmitted via the HCND to the VSD, lowering the energy barrier for channel opening (Porro et al., 2019; Wang et al., 2020). The mutants that disrupt the contact between the CNBD and the HCND eliminate the effect of cAMP on channel activation (Porro et al., 2019; Wang et al., 2020). Results of the molecular modeling demonstrated that the interaction between CNBD and HCND is not affected by the p.V240M mutation (Figure 12C). The latter would explain why p.V240M channels are sensitive to cAMP. Interestingly, our results demonstrated that p.V240M mutation markedly increases single HCN4 channel conductance, an effect that is beyond the positive shift of the activation curve. We propose that somewhat the mutation introduces changes in the pore region that controls the conductance of the channel, even when the channel selectivity is not affected. In summary, and considering that there are very few reports describing single-channel currents generated by HCN4 channels (Brandt et al., 2009; Michels et al., 2005), our results contribute to the understanding of the role of HCND in the distinctive biophysical properties of these channels. The HCND is also necessary for the folding and trafficking of the channel to the plasma membrane (Porro et al., 2019; Wang et al., 2020). To the best of our knowledge, the only naturally occurring HCND mutation described so far is p.P257S which was identified in patients with early-onset atrial fibrillation (Macri et al., 2014). p.P257S channels present a trafficking defect being retained at the endoplasmic reticulum (Macri et al., 2014). Conversely, the p.V240M mutant is properly expressed in the membrane suggesting that p.V240M mutation does not affect the folding and trafficking of HCN4 subunits. **Clinical implications** IST is a relatively common clinical entity producing highly distressing symptoms. In most cases, it is a sporadic non-familial-disease. Here we describe an autosomal-dominant form of IST with a striking complete penetrance. The clinical manifestations of the carriers are noteworthy, as

they presented with systolic dysfunction. In fact, IST is barely associated with heart dysfunction

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

and tachycardia-induced cardiomyopathy (Olshansky and Sullivan, 2019; Sheldon et al., 2015a) although some cases have been already reported (Romeo et al., 2011; Winum et al., 2009). Even when HCN4 mutations have been related with noncompaction cardiomyopathy (Alonso-Fernández-Gatta et al., 2021), no signs of hypertrabeculation were found with CMR imaging or echocardiography in this family. The fact that ivabradine reversed systolic ventricular dysfunction suggests that the high HR and the duration of the arrhythmia (present from childhood but being documented even before birth in 2 patients) could have been the major contributors to cardiac dysfunction in our patients. Regarding treatment of IST, carriers were treated with ivabradine, since previous reports demonstrated that it reduced HR and improved quality of life in patients with IST (Cappato et al., 2012). Interestingly, the HR reduction in our study with ivabradine alone was ≈14% which is similar to that obtained previously in patients with IST of an unknown origin (Benezet-Mazuecos et al., 2013; Cappato et al., 2012). Responsiveness of our patients to ivabradine can be explained considering that sensitivity of p.V240M channels was identical to that of WT HCN4. These results strengthen the importance of genetic and functional studies for the design of personalized therapies in patients with inherited arrhythmogenic syndromes. The degree of activation of I_f at the end of an AP determines the steepness of phase 4 depolarization; hence, the frequency of AP firing (Verkerk and Wilders, 2015). Thus, it seems reasonable to assume that the gain-of-function p.V240M mutation is responsible for an increase in sinoatrial node automaticity and the IST of the affected subjects in this family.

Conclusions

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

Our results support the view that individuals carrying the p.V240M mutation present higher than normal I_{HCN4} . This variant increases I_{HCN4} by an unprecedented mechanism that implies the alteration of the gating without modifying the channel sensitivity for cAMP or the membrane expression. Therefore, p.V240M is the first naturally occurring gain-of-function HCND variant which explains the faster than normal HR and IST of the carriers. The clinical, genetic and functional study of the variant led to the establishment of the personalized treatment with ivabradine for all carriers, contribute to shed light in the understanding of the pathophysiology of IST and help to the understanding the role of HCN4 channels in the pacemaker activity of human sinoatrial cells.

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

Methods

433

434

435

436437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458 459

460

461

462

463

Study approval.

All patients signed an informed consent, and the study was approved by the Research Ethics Committee of Granada (ref: CEIM/CEI/3-19 [12/4/19]. The purpose, methods and ethical aspects of this specific study were specifically assessed in an ordinary meeting of the Committee. Moreover, the study conforms to the principles outlined in the Declaration of Helsinki. Genetic results of the participants were reported following the guidelines proposed by the Working Group on Reporting Genetic Results in Research Studies (Bookman et al., 2006).

Clinical study.

The proband and relatives of a Spanish family with several members diagnosed with IST and left ventricular (LV) systolic dysfunction were evaluated at the "Hereditary cardiovascular disease unit" in the Cardiology Department of the Hospital Universitario Virgen de las Nieves. Trained personnel performed at least three electrocardiograms ECG at rest to the proband and to all the family members that gave their written informed consent. Family members either diagnosed or not with IST underwent a serial 24-hour ECG monitoring (at least two for patients diagnosed with IST). CMR was performed only to adult family members with IST. Three months after initiation of medical therapy with ivabradine (7.5 mg BID in adults, 5 mg BID in children) or ivabradine (5 mg BID) plus bisoprolol (5 mg BID), the 24-h Holter monitoring and echocardiogram were repeated for every patient, and the findings were compared with those obtained before treatment. The size of chamber, quantifications, and severity partition cut-offs of LV dysfunction were measured according to the current guidelines (Sheldon et al., 2015b). IST was defined as fast sinus rates (>100 bpm at rest or >90 bpm on average over 24 h) not due to underlying causes. Thus, prior to IST diagnosis, other causes such as hyperthyroidism, anemia, diabetes mellitus, orthostatic hypotension, infections, and drug abuse, were ruled out. A full pedigree was obtained collecting information such as cardiac events (sudden cardiac death, heart transplantation or device implantation), cases of IST, or systolic dysfunction of unknown etiology and any kind of cardiomyopathy across 4 generations. Echocardiographic, ECG, and imaging recordings were interpreted by experienced cardiologists, blinded to the genetic and clinical data of the participants. QT values were corrected using the Bazzet's and Fredericia's formulas in subjects with HR <100 and ≥100 bpm, respectively.

Next-generation and Sanger sequencing.

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

464

465

466

467

468

469

470

471 472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

The genetic analysis of the proband was conducted by using a next-generation sequencing panel including 197 genes (Table Supplement File 1) following procedures previously described (Caballero et al., 2017; Nieto-Marín et al., 2022). Genomic DNA was extracted using an automated extraction and purification process by using the QIAsymphony SP® kit (Qiagen, Hilde, Germany) according to the manufacturer's instructions. Library preparation was carried out using SureSelect Reagent kit (Agilent, Santa Clara, CA, USA) for Illumina's paired-end multiplexed sequencing method, following the manufacturer's instructions. The enrichment of the regions of interest was performed by means of a SureSelect (Agilent) probe kit that selectively captures the coding zones and the flanking intronic areas of the selected genes. After the generation of clusters, the DNA libraries were sequenced on the Illumina HiSeq 1500 platform. The analysis of the sequencing data was performed using a proprietary bioinformatics pipeline to obtain a report of variants noted along with their coverage and corresponding quality parameters. We excluded variants located in introns (except those in suspected splicing sites) or intergenic regions. We also removed synonymous variants and non-synonymous variants with occurrences >1 in our local database. The list of variants identified were evaluated against database information on previously described variants [Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/), Single Nucleotide Polymorphism (SNP) database (http://www.ncbi.nlm.nih.gov/SNP/), NHLBI Exome GO Sequencing Project (https://www.ncbi.nlm.nih.gov/clinvar/), (http://evs.gs.washington.edu/EVS), ClinVar Genome Aggregation database (http://gnomad.broadinstitute.org). Pathogenicity of the identified variants was established according to the current recommendations of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (Richards et al., 2015). Variant pathogenicity was graded according to its presence in a previously associated or candidate gene and the in silico predicted impact on the protein using widely used software (PROVEAN, SIFT, Polyphen2, Mutation Taster, and Combined Annotation Dependent Depletion Score), the degree of conservation of the affected residue measured by multiple ortholog alignment using Alamut software (http://www.interactive-biosoftware.com). A phenotype-genotype segregation study was conducted through cascade screening among available relatives with Sanger genetic study (Caballero et al., 2017; Nieto-Marín et al., 2022). PCR products were purified using illustra ExoProStar 1-Step (GE Healthcare Life Sciences, Chicago, IL, USA) and the analysis was performed by direct sequencing (Health in Code, A Coruña, Spain). The results were compared with the reference sequence from hg19 by means of Chromas Lite Software (http://technelysium.com.au).

Cell culture and transfection.

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515 516

517

518

519

520

521 522

523

524

525

526

527

528

529

530

531

The study has been conducted in CHO and HEK-293 purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). They had been authenticated by the supplier as appropriate. Mycoplasma tests were conducted routinely for both cell lines and showed no mycoplasma contamination. CHO cells were grown in Ham-F12 medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin (Caballero et al., 2010; Caballero et al., 2017; Pérez-Hernández et al., 2018; Alonso-Fernández-Gatta et al., 2021; Crespo-García et al., 2023). HEK-293 cells were cultured in Dulbecco's modified Eagle's (DMEM) medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin as previously described (Caballero et al., 2010; Crespo-García et al., 2023). The cultures were passed every 2-5 days using a brief trypsin treatment. The p.V240M HCN4 mutation (NP 005468.1) was introduced by using the QuikChange Site-Directed Mutagenesis kit (Agilent, Santa Clara, CA, USA) and confirmed by direct DNA sequencing (Secugen S.L., Madrid, Spain). The sequence of the oligonucleotides used to 5′ introduce the p.V240M substitution the following: was sense 5' GCAGCCAGAAAGCCaTGGAGCGCGAACAG 3'; antisense CTGTTCGCGCTCCAtGGCTTTCTGGCTGC 3'. The sequence of the oligonucleotide used for sequencing was: 5' ACGGACACCTGCATGACTC 3'. For macroscopic current recordings, subconfluent cultures were transiently transfected with cDNA encoding WT or mutated HCN4 channels (1.6 µg) together with cDNA encoding the CD8 antigen (0.5 μg) by using X-tremeGENE™ HP (Roche Diagnostics, Rotkreuz, Switzerland) in CHO cells or Lipofectamine 2000 (Thermofisher Scientific, Waltham, MA, USA) in HEK-293 cells, with manufacturer instructions followed (Caballero et al., 2010; Caballero et al., 2017; Pérez-Hernández et al., 2018; Alonso-Fernández-Gatta et al., 2021; Crespo-García et al., 2023). In some experiments, WT and p.V240M HCN4 were cotransfected (WT+p.V240M) at a 0.5:0.5 ratio (0.8 μg each). For single channel recordings, CHO cells were transfected with 0.5 instead of 1.6 μg of the cDNA encoding mutated or WT HCN4. In all cases, at the point of 48 h after transfection, cells were incubated with polystyrene microbeads precoated with anti-CD8 antibody (Dynabeads M450, Thermofisher Scientific). Most of the cells that were beaded also exhibited channel expression. The day of recordings, cells were removed from the dish by using a cell scraper or by trypsinization, respectively, and the cell suspension was stored at room temperature and used within 12 h for electrophysiological experiments.

To minimize the influence of the expression variability, each construct was tested in a large number of cells obtained from at least 3 different cell batches. Moreover, to avoid putative interferences of culture conditions (passage number, cell density, etc), currents generated by cells expressing WT, p.V240M and WT+p.V240M channels were always recorded in parallel.

Recording techniques.

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

Macroscopic current recordings.

A small aliquot of cell suspension was placed in a 0.5 ml chamber mounted on the stage of an inverted microscope (Nikon TMS; Nikon Co., Tokio, Japan). After settling to the bottom of the chamber, cells were perfused at ≈1 mL/min with external solution (see the composition below). Macroscopic currents were recorded at room temperature (21-23°C) by means of the wholecell patch-clamp technique using Axopatch-200B patch clamp amplifiers and pCLAMP software (Molecular Devices, San José, CA, USA) (Caballero et al., 2010; Caballero et al., 2017; Pérez-Hernández et al., 2018; Alonso-Fernández-Gatta et al., 2021; Nieto-Marín et al., 2022; Crespo-García et al., 2023) Recording pipettes were pulled from 1.0 mm o.d. borosilicate capillary tubes (GD1, Narishige Co., Ltd, Tokio, Japan) using a programmable patch micropipette puller (Model P-2000 Brown-Flaming, Sutter Instruments Co., Novato, CA, USA) and were heat-polished with a microforge (Model MF-83, Narishige). Micropipette resistance ranged 3-5 M Ω when filled with the internal solution and immersed in the external solution. In all the experiments, series resistance was compensated manually by using the series resistance compensation unit of the Axopatch amplifier, and ≥80% compensation was achieved. The remaining access resistance after compensation and cell capacitance were $1.7\pm0.4 \text{ M}\Omega$ and $11.9\pm0.7 \text{ pF}$ (n=65), respectively. Therefore, under our experimental conditions no significant voltage errors (<5 mV) due to series resistance were expected with the micropipettes used. Currents were filtered at half the sampling frequency and stored on the hard disk of a computer for subsequent analysis. CHO cells were perfused with an external solution containing (mM): NaCl 110, KCl 30, HEPES 5, MgCl₂ 0.5, CaCl₂ 1.8, and glucose 10; pH= 7.4 with NaOH. Recording pipettes were filled with an internal solution containing (mM): K-aspartate 80, KCl 42, KH₂PO₄ 10, MgATP 5, phosphocreatine 3, HEPES 5 and EGTA 5; pH 7.2 with KOH. The protocol to obtain current-voltage relationships consisted of 2-s steps that were imposed in 10 mV increments from a holding potential of -40 mV to potentials ranging -160 and 0 mV. Current amplitude was measured at the end of the pulse and normalized in each experiment to membrane capacitance to obtain current densities. To determine putative effects on the ion selectivity of HCN4 channels, the reversal potential

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

(E_{rev}) was measured at extracellular and intracellular K⁺ concentrations of 30 and 142 mM, respectively. To this end, 3-s pulses to -120 mV followed by 1-s pulse to membrane potentials ranging -50 to +20 mV were applied. The Erev was calculated in each experiment from the intersection of the linear regression to the data with the abscissas axis. To analyze potential effects on the time course of current activation, a monoexponential function was fitted to the activation phase of current traces elicited by pulses to −160 mV yielding τ_{act} that defines the process. To measure HCN4 deactivation kinetics, two 3-s pulses from −40 to −120 mV were applied at increasing coupling intervals (1-6 s) (Mistrík et al., 2006; Schweizer et al., 2010). This protocol allowed us to calculate, for each coupling interval, the ratio between ΔI_{INS} and I_{SS} elicited at the beginning and at the end, respectively, of the second pulse to −120 mV. The calculated ratio was plotted as a function of the coupling interval and a monoexponential function was fitted to the data to obtain the τ_{deact} . The protocol to analyze the voltage dependence of HCN4 channel activation consisted of 2-s pulses from −40 mV to potentials ranging from −160 to 0 mV followed by 1-s pulses to −140 mV to record the tail currents. The tail current amplitude was normalized to the maximum value and plotted as a function of the membrane potential of the preceding pulse to construct the activation curves. A Boltzmann function was fitted to the data to calculate the midpoint (V_b) and the slope (k) of the curves. In a subset of experiments, the consequences of the p.V240M variant on the shift of the voltage-dependent activation produced by of 3',5'-cyclic Adenosine monophosphate (cAMP) were analyzed in HEK-293 cells. It has been recently described that in CHO but not in HEK-293 cells, HCN4 channel activation is constitutively shifted to more depolarized membrane potentials and is no longer affected by cAMP (Peters et al., 2020). In these experiments, HEK-293 cells cultured and transfected as described above, were perfused with the same external solution than described for CHO cells (see above), while the internal solution contained (mM): KCl 130, NaCl 10, MgATP 2, HEPES 5, MgCl₂ 0.5 and EGTA 1; pH 7.2 with KOH. cAMP (Merck, Rahway, NJ, USA) at a saturating concentration (10 μM) was added to the pipette solution. The effects of different concentrations of ivabradine (0.1-3 µM) was determined in CHO cells transfected with WT or p.V240M HCN4 channels by applying trains of activating/deactivating steps to -140 and +5 mV from a holding potential of -35 mV (Bucchi et al., 2013). The I_{HCN4} inhibition at -140 mV was used as an index of block (f; expressed as percentage of inhibition) to construct the respective concentration-response curves and a Hill equation (f = $1/\{1+(IC_{50}/[D])^{nH}\}$) was fitted to the data to obtain the concentration needed to produce the 50% of the maximum inhibition (IC₅₀). In the fit, n_H was fixed to unity and bottom and top values were constrained to 0 and 100%, respectively.

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

Single channel recordings.

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

Single channel currents were recorded in CHO cells at room temperature (21-23 °C) using the cell-attached patch-clamp configuration (Michels et al., 2005; Brandt et al., 2009; Caballero et al., 2010; Crespo-García et al., 2023). Using this configuration, the intracellular environment is completely preserved and channel activity can be measured in an intact cell. Cells were suspended in bath solution containing (mM): KCl 130, NaCl 10, EGTA 5 and HEPES 10; pH 7.4 with KOH. This high-K⁺ solution was used to achieve a resting membrane potential of zero. Patch pipettes were pulled from 1.5 mm o.d. borosilicate capillary tubes (Harvard Apparatus Ltd, Holliston, MA, USA), coated at the tip with Sylgard (Dow Corning, Midland, MI, USA), and firepolished with a microforge (Mod. MF-830. Narishige). When filled with pipette solution containing (in mM): KCl 70, NaCl 70, MgCl₂ 1, BaCl₂ 2 and HEPES 5; pH 7.4 with KOH, tip resistances were between 5 and 10 M Ω . The micropipettes were gently lowered onto the cells to get a gigaohm seal after applying suction. After seal formation, the cells were lifted from the bottom of the perfusion bath and current recordings were started. Single channel currents were recorded by applying repetitive 10-s pulses from a holding potential of -35 mV to -90 mV or to potentials between -120 and +40 mV in 10 mV steps. Current data were sampled at 10 kHz and filtered at 1 kHz. The apparent number of active channels in a patch was determined by visual inspection of the current traces and patches with more than one channel were discarded. The experimental conditions were optimized to reduce the number of active channels on each recording: e.g., the amount of cDNA used for cell transfection was reduced by ≈70% and the tip resistance of the pipettes was increased approximately threefold compared to whole-cell recordings. Under these conditions, only 10% of cells with active channels had more than one channel. All data analysis was performed by using pCLAMP software and opening events were captured using the event detection tool of Clampfit 10 (Caballero et al., 2010; Crespo-García et al., 2023). At the end of each experiment, the HCN channel inhibitor ivabradine (5 μ M) (Bucchi et al., 2006) was added to the external solution to specifically abolish single channel currents generated by HCN4 channels. Amplitude of unitary currents was determined for each experiment by direct measurements of

fully resolved openings, which allowed the calculation of average values. The opening

probability (P_0) was obtained for each experiment by dividing the time that the channel remains

in the open state by the total recording time and the opening frequency (f_0) was calculated for

each experiment as the inverse of the closed time between events. The mean open time was

calculated for each experiment by dividing the time the channel remains in the open state by the events. To measure opening and closing kinetics, dwell-time histograms were constructed by plotting pooled dwell-time data as a function of the number of events per bin that were fitted by monoexponential functions to calculate τ_{OPEN} and τ_{CLOSED}. Current–voltage relationships were constructed by plotting the single channel current amplitude as a function of the membrane potential and conductance (y) was calculated from the slope of the fit of a linear function to the data recorded at potentials between -120 and -60 mV.

Biotinylation assay.

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

A biotinylation assay was conducted in CHO cells using procedures previously described (Crespo-García et al., 2023). At the point of 48 h after transfection of HCN4 WT or p.V240M, CHO cells were washed twice with ice cold phosphate-buffer saline (PBS) and biotinylated for 15 min at 4°C using PBS containing 0.5 mg/mL of EZ Link Sulfo-NHS-SS-Biotin (ThermoFisher). Plates were washed twice with PBS-200 mM glycine (to quench unlinked biotin) and again with PBS. Cells were collected in RIPA buffer containing 50 mM Tris·HCl (pH=7.5), 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 0.5% sodium deoxycholate, and 1 mM phenylmethylsulfonyl fluoride (PMSF) and protease inhibitor cocktail (Merck) for protein extraction. Subsequently, the extract (1 mg) was incubated with Streptavidin Sepharose (50 μl, GE Healthcare) overnight at 4°C. To separate biotinylated fraction, samples were centrifugated at 3000 rpm for 2 min at 4°C. The fraction of biotinylated proteins was washed by several centrifugations. Thereafter, HCN4 and ezrin proteins were detected by Western blot following previously described procedures (Pérez-Hernández et al., 2018; Nieto-Marín et al., 2022; Crespo-García et al., 2023). Nuclei and cell debris were removed by centrifugation at 14.000 rpm for 20 min at 4°C. The total protein amount of the extracts was calculated with the bicinchoninic acid method (Pierce™ BCA Protein Assay Kit, ThermoFisher). Samples were run on 4-15% Mini-PROTEAN TGXTM stain-free gels (Bio-Rad, Hércules, CA, USA USA) and, afterwards, protein was transferred to nitrocellulose membranes. Nonspecific binding sites were blocked with 5% non-fat dried milk in PBS with Tween-20 (0.05%) for 1 hour at room temperature. Membranes were then incubated with rabbit polyclonal anti-HCN4 (1:1000; 55224-1-AP, Proteintech, Rosemont, IL, USA) and mouse monoclonal anti-ezrin (1:400; ab4069, Abcam, Cambridge, UK) primary antibodies overnight at 4°C. All the antibodies had been validated by the manufacturers. After the incubation with the primary antibodies, samples were incubated for 1 hour with peroxidase-conjugated goat antirabbit (111-035-144) or goat anti-mouse (115-035-003) secondary antibody (1:10000; Jackson

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682 683

684

685

686

687

688

689

690

691

692

693

694

695

696

Immunoresearch, West Grove, PA, USA). Membranes were washed three times with PBS-Tween after adding primary and secondary antibodies. Protein expression was detected by chemiluminescence (SuperSignal™ West Femto Maximum Sensitivity Substrate, ThermoFisher) and visualized using the Chemidoc MP System and Image Lab 5.2.1. software (Bio-Rad). Expression of the proteins in the biotinylated (membrane) fraction was normalized to the input expression.

Mathematical modeling of human sinoatrial node action potential.

We employed the Fabbri-Fantini-Wilders-Severi model of human sinus node cells (Fabbri et al., 2017). The model is based on experimental recordings and numerical reconstructions of the I_f measured in human sinoatrial node cells (Verkerk et al., 2007a, 2007b) and fairly reproduces the changes in heart rate induced by mutations or drugs affecting the If (Fabbri et al., 2017). We downloaded the model files available at the CellML model (http://models.cellml.org/cellml), as part of the International Union of Physiological Sciences Physiome Project (Yu et al., 2011). To perform the simulations we used OpenCell software package that allows reading, modifying, solving, and plotting CellML models (http://cellmlopencell.hg.sourceforge.net:8000/hgroot/cellml-opencell/cellml-opencell). Initially, the model was run (for 100 s) keeping all parameters at their default values and under these conditions, the model was stable and reproduced the results obtained in the original description of the model (Fabbri et al., 2017). The results obtained with these "basal" conditions were considered to correspond to WT HCN4. Thereafter, the experimentally measured changes produced by p.V240M HCN4 or WT + p.V240M HCN4 on the conductance, kinetics and voltage dependence of activation of the macroscopic If were incorporated into the model equations corresponding to the I_f. The modified versions of the model were also run for 100 s. In all cases, we plotted action potential and If traces yielded at the end of the simulation runs and several parameters were measured including cycle length, beating frequency, diastolic depolarization rate, mean diastolic potential, action potential amplitude, overshoot, and action potential duration measured at 20, 50, and 90% of repolarization.

Molecular modeling.

To estimate the conformational changes produced by the p.V240M HCN4 mutation a molecular modeling using the crystallized structure of human HCN4 (PDB: 6GYN) was performed. Model refinement, in silico mutagenesis, and energy calculation were done with FoldX Suite (version

4.0, https://www.foldxsuite.crg.eu). For model refinement and minimizing the energy of the structure, the RepairPDB protocol was used. The Val-to-Met substitution at position 240 of each monomer of the optimized PDB was performed and the protocol to calculate free energies was run ten times. Default parameters of the software were used except temperature, pH, ionic strength and VdW design that were set at 298K, 7, 5 and 0, respectively. When the model running was completed, the software provided different conformations with different energies and the conformation of the mutated form with the lowest energy was chosen. The optimized conformations of WT and p.V240M HCN4 were compared on PyMOL (Molecular Graphics System, Version 2.0 Schrödinger, LLC; https://www.pymol.org/2/) and putative changes in the aminoacid positions and interactions (Hydrophobic, electrostatic and H-Bonds) with surrounding residues induced by the presence of the mutation were identified (Caballero et al, 2010).

Statistical Analyses

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

Clinical and experimental results are expressed as mean[SD] and mean±SEM, respectively. Small-sized samples were first analyzed to determine the distribution of the variables (Normality) using the Shapiro-Wilk and Kilmogorov-Smirnov tests. When these tests demonstrated a normal distribution, parametric tests were used. Paired or unpaired t test, multiple t test, one-way ANOVA followed by Tukey's test, or two-way ANOVA were used to assess statistical significance where appropriate. When a statistically significant difference was determined by these tests, a Pearson correlation was performed to confirm that the observed differences were not due to random sampling. To make comparisons between fits of pooled or of concentration-dependent data, an F-test was used. Variance was comparable between groups throughout the manuscript. A value of P<0.05 was considered significant. Statistical tests were conducted using GraphPad Prism 8 (https://www.graphpad.com/scientificsoftware/prism/) or Microsoft Excel. For the different groups of experiments sample size was chosen empirically according to previous experience in the calculation of experimental variability. No statistical method was used to predetermine sample size. The cellular experiments were not blinded due to the nature of the experimental design and platforms but all the data were analysed in an identical manner for all conditions to eliminate possible operator bias.

Data availability

728

732

733

734

- 729 All data generated or analyzed during this study are included in the manuscript and supporting
- 730 files. CMR and acute and Holter ECGs recordings will be not available since they are incorporated
- 731 into the confidential medical record of each participant.

Disclosures

The authors declare no conflict of interest

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

REFERENCES

735

753

754

755

756

760 761

762

763

764

765

766

767

771

772

- Alonso-Fernández-Gatta M, Gallego-Delgado M, Caballero R, Villacorta E, Díaz-Peláez E, García Berrocal B, Crespo-García T, Plata-Izquierdo B, Marcos-Vadillo E, García-Cuenllas L,
 Barreiro-Pérez M, Isidoro-García M, Tamargo-Menéndez J, Delpón E, Sánchez PL. 2021. A
- rare HCN4 variant with combined sinus bradycardia, left atrial dilatation, and
- hypertrabeculation/left ventricular noncompaction phenotype. *Rev Espanola Cardiol Engl Ed* **74**:781–789. doi:10.1016/j.rec.2020.06.019
- Baruscotti M, Bianco E, Bucchi A, DiFrancesco D. 2016. Current understanding of the
 pathophysiological mechanisms responsible for inappropriate sinus tachycardia: role of
 the If "funny" current. *J Interv Card Electrophysiol Int J Arrhythm Pacing* 46:19–28.
 doi:10.1007/s10840-015-0097-y
- Baruscotti M, Bucchi A, Difrancesco D. 2005. Physiology and pharmacology of the cardiac
 pacemaker ("funny") current. *Pharmacol Ther* 107:59–79.
 doi:10.1016/j.pharmthera.2005.01.005
- Baruscotti M, Bucchi A, Milanesi R, Paina M, Barbuti A, Gnecchi-Ruscone T, Bianco E, Vitali Serdoz L, Cappato R, DiFrancesco D. 2017. A gain-of-function mutation in the cardiac
 pacemaker HCN4 channel increasing cAMP sensitivity is associated with familial
 Inappropriate Sinus Tachycardia. Eur Heart J 38:280–288. doi:10.1093/eurheartj/ehv582
 - Benezet-Mazuecos J, Rubio JM, Farré J, Quiñones MÁ, Sanchez-Borque P, Macía E. 2013. Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients. *Pacing Clin Electrophysiol PACE* **36**:830–836. doi:10.1111/pace.12118
- Biel M, Wahl-Schott C, Michalakis S, Zong X. 2009. Hyperpolarization-activated cation
 channels: from genes to function. *Physiol Rev* 89:847–885.
 doi:10.1152/physrev.00029.2008
 - Bookman EB, Langehorne AA, Eckfeldt JH, Glass KC, Jarvik GP, Klag M, Koski G, Motulsky A, Wilfond B, Manolio TA, Fabsitz RR, Luepker RV; NHLBI Working Group. 2006. Reporting genetic results in research studies: summary and recommendations of an NHLBI working group. Am J Med Genet A. 140:1033-1040. doi: 0.1002/ajmg.a.31195.
 - Brandt MC, Endres-Becker J, Zagidullin N, Motloch LJ, Er F, Rottlaender D, Michels G, Herzig S, Hoppe UC. 2009. Effects of KCNE2 on HCN isoforms: distinct modulation of membrane expression and single channel properties. *Am J Physiol Heart Circ Physiol* **297**:H355-363. doi:10.1152/ajpheart.00154.2009
- Bucchi A, Tognati A, Milanesi R, Baruscotti M, DiFrancesco D. 2006. Properties of ivabradine induced block of HCN1 and HCN4 pacemaker channels. *J Physiol* 572:335–346.
 doi:10.1113/jphysiol.2005.100776
 - Bucchi A, Baruscotti M, Nardini M, Barbuti A, Micheloni S, Bolognesi M, DiFrancesco D. 2013. Identification of the molecular site of ivabradine binding to HCN4 channels. PLoS One 8:e53132. doi:10.1371/journal.pone.0053132
- Caballero R, Dolz-Gaitón P, Gómez R, Amorós I, Barana A, González de la Fuente M, Osuna L,
 Duarte J, López-Izquierdo A, Moraleda I, Gálvez E, Sánchez-Chapula JA, Tamargo J, Delpón
 E. 2010. Flecainide increases Kir2.1 currents by interacting with cysteine 311, decreasing
 the polyamine-induced rectification. *Proc Natl Acad Sci U S A* 107:15631–15636.
 doi:10.1073/pnas.1004021107
- Caballero R, Utrilla RG, Amorós I, Matamoros M, Pérez-Hernández M, Tinaquero D, Alfayate S,
 Nieto-Marín P, Guerrero-Serna G, Liu Q-H, Ramos-Mondragón R, Ponce-Balbuena D,
- Herron T, Campbell KF, Filgueiras-Rama D, Peinado R, López-Sendón JL, Jalife J, Delpón E, Tamargo J. 2017. Tbx20 controls the expression of the *KCNH2* gene and of hERG channels.
- 783 *Proc Natl Acad Sci U S A* **114**:E416–E425. doi:10.1073/pnas.1612383114

791

792

793

794

795

796

797

798

799

800

801

802

803 804

805

806

807

814

815

816

817

818

819

- Cambon-Viala M, Gerard H, Nguyen K, Richard P, Ader F, Pruny J-F, Donal E, Eicher J-C, Huttin
 O, Selton-Suty C, Raud-Raynier P, Jondeau G, Mansencal N, Sawka C, Casalta A-C, Michel
 N, Donghi V, Martel H, Faivre L, Charron P, Habib G. 2021. Phenotype/Genotype
 Relationship in Left Ventricular Noncompaction: Ion Channel Gene Mutations Are
 Associated With Preserved Left Ventricular Systolic Function and Biventricular
 Noncompaction: Phenotype/Genotype of Noncompaction. *J Card Fail* 27:677–681.
 doi:10.1016/j.cardfail.2021.01.007
 - Cappato R, Castelvecchio S, Ricci C, Bianco E, Vitali-Serdoz L, Gnecchi-Ruscone T, Pittalis M, De Ambroggi L, Baruscotti M, Gaeta M, Furlanello F, Di Francesco D, Lupo PP. 2012. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. *J Am Coll Cardiol* **60**:1323–1329. doi:10.1016/j.jacc.2012.06.031
 - Chiale PA, Garro HA, Schmidberg J, Sánchez RA, Acunzo RS, Lago M, Levy G, Levin M. 2006. Inappropriate sinus tachycardia may be related to an immunologic disorder involving cardiac beta andrenergic receptors. *Heart Rhythm* **3**:1182–1186. doi:10.1016/j.hrthm.2006.06.011
 - Crespo-García T, Rubio-Alarcón M, Cámara-Checa A, Dago M, Rapún J, Nieto-Marín P, Marín M, Cebrián J, Tamargo J, Delpón E, Caballero R. 2023. A Cantú syndrome mutation produces dual effects on KATP channels by disrupting ankyrin B regulation. *J Gen Physiol* **155**:e202112995. doi:10.1085/jgp.202112995
 - DiFrancesco D. 2010. The role of the funny current in pacemaker activity. *Circ Res* **106**:434–446. doi:10.1161/CIRCRESAHA.109.208041
 - DiFrancesco D, Tortora P. 1991. Direct activation of cardiac pacemaker channels by intracellular cyclic AMP. *Nature* **351**:145–147. doi:10.1038/351145a0
- DiFrancesco JC, Castellotti B, Milanesi R, Ragona F, Freri E, Canafoglia L, Franceschetti S,
 Ferrarese C, Magri S, Taroni F, Costa C, Labate A, Gambardella A, Solazzi R, Binda A,
 Rivolta I, Di Gennaro G, Casciato S, D'Incerti L, Barbuti A, DiFrancesco D, Granata T,
 Gellera C. 2019. HCN ion channels and accessory proteins in epilepsy: genetic analysis of a
 large cohort of patients and review of the literature. *Epilepsy Res* **153**:49–58.
 doi:10.1016/j.eplepsyres.2019.04.004
 - Duhme N, Schweizer PA, Thomas D, Becker R, Schröter J, Barends TRM, Schlichting I, Draguhn A, Bruehl C, Katus HA, Koenen M. 2013. Altered HCN4 channel C-linker interaction is associated with familial tachycardia-bradycardia syndrome and atrial fibrillation. *Eur Heart J* 34:2768–2775. doi:10.1093/eurheartj/ehs391
 - Fabbri A, Fantini M, Wilders R, Severi S. 2017. Computational analysis of the human sinus node action potential: model development and effects of mutations. *J Physiol* **595**:2365–2396. doi:10.1113/JP273259
- He J-T, Li X-Y, Zhao X, Liu X. 2019. Hyperpolarization-activated and cyclic nucleotide-gated channel proteins as emerging new targets in neuropathic pain. *Rev Neurosci* **30**:639–649. doi:10.1515/revneuro-2018-0094
- Hennis K, Biel M, Fenske S, Wahl-Schott C. 2022. Paradigm shift: new concepts for HCN4 function in cardiac pacemaking. *Pflugers Arch* **474**:649–663. doi:10.1007/s00424-022-02698-4
- Lee C-H, MacKinnon R. 2017. Structures of the Human HCN1 Hyperpolarization-Activated Channel. *Cell* **168**:111-120.e11. doi:10.1016/j.cell.2016.12.023
- Li N, Artiga E, Kalyanasundaram A, Hansen BJ, Webb A, Pietrzak M, Biesiadecki B, Whitson B,
 Mokadam NA, Janssen PML, Hummel JD, Mohler PJ, Dobrzynski H, Fedorov VV. 2021.
 Altered microRNA and mRNA profiles during heart failure in the human sinoatrial node.
- 832 *Sci Rep* **11**:19328. doi:10.1038/s41598-021-98580-x
- Li N, Csepe TA, Hansen BJ, Dobrzynski H, Higgins RSD, Kilic A, Mohler PJ, Janssen PML, Rosen MR, Biesiadecki BJ, Fedorov VV. 2015. Molecular Mapping of Sinoatrial Node HCN Channel

857

858

859 860

861

862

863

864

865

866

867

868 869

870

871

876

877

878

879

880

881

```
Expression in the Human Heart. Circ Arrhythm Electrophysiol 8:1219–1227. doi:10.1161/CIRCEP.115.003070
```

- Macri V, Mahida SN, Zhang ML, Sinner MF, Dolmatova EV, Tucker NR, McLellan M, Shea MA,
 Milan DJ, Lunetta KL, Benjamin EJ, Ellinor PT. 2014. A novel trafficking-defective HCN4
 mutation is associated with early-onset atrial fibrillation. *Heart Rhythm* 11:1055–1062.
 doi:10.1016/j.hrthm.2014.03.002
- Michels G, Er F, Khan I, Südkamp M, Herzig S, Hoppe UC. 2005. Single-channel properties support a potential contribution of hyperpolarization-activated cyclic nucleotide-gated channels and If to cardiac arrhythmias. *Circulation* **111**:399–404. doi:10.1161/01.CIR.0000153799.65783.3A
- Milanesi R, Baruscotti M, Gnecchi-Ruscone T, DiFrancesco D. 2006. Familial sinus bradycardia associated with a mutation in the cardiac pacemaker channel. *N Engl J Med* **354**:151–157. doi:10.1056/NEJMoa052475
- Mistrík P, Pfeifer A, Biel M. 2006. The enhancement of HCN channel instantaneous current facilitated by slow deactivation is regulated by intracellular chloride concentration.

 Pflugers Arch 452:718–727. doi:10.1007/s00424-006-0095-0
- Nieto-Marín P, Tinaquero D, Utrilla RG, Cebrián J, González-Guerra A, Crespo-García T, Cámara-Checa A, Rubio-Alarcón M, Dago M, Alfayate S, Filgueiras-Rama D, Peinado R, López-Sendón JL, Jalife J, Tamargo J, Bernal JA, Caballero R, Delpón E, ITACA Consortium Investigators. 2022. Tbx5 variants disrupt Nav1.5 function differently in patients diagnosed with Brugada or Long QT Syndrome. *Cardiovasc Res* 118:1046–1060. doi:10.1093/cvr/cvab045
 - Nof E, Luria D, Brass D, Marek D, Lahat H, Reznik-Wolf H, Pras E, Dascal N, Eldar M, Glikson M. 2007. Point mutation in the HCN4 cardiac ion channel pore affecting synthesis, trafficking, and functional expression is associated with familial asymptomatic sinus bradycardia. *Circulation* **116**:463–470. doi:10.1161/CIRCULATIONAHA.107.706887
 - Nwazue VC, Paranjape SY, Black BK, Biaggioni I, Diedrich A, Dupont WD, Robertson D, Raj SR. 2014. Postural tachycardia syndrome and inappropriate sinus tachycardia: role of autonomic modulation and sinus node automaticity. *J Am Heart Assoc* **3**:e000700. doi:10.1161/JAHA.113.000700
 - Olshansky B, Sullivan RM. 2019. Inappropriate sinus tachycardia. *EP Eur* **21**:194–207. doi:10.1093/europace/euy128
 - Pérez-Hernández M, Matamoros M, Alfayate S, Nieto-Marín P, Utrilla RG, Tinaquero D, de Andrés R, Crespo T, Ponce-Balbuena D, Willis BC, Jiménez-Vazquez EN, Guerrero-Serna G, da Rocha AM, Campbell K, Herron TJ, Díez-Guerra FJ, Tamargo J, Jalife J, Caballero R, Delpón E. 2018. Brugada syndrome trafficking-defective Nav1.5 channels can trap cardiac Kir2.1/2.2 channels. *JCI Insight* 3. doi:10.1172/jci.insight.96291
- Peters CH, Myers ME, Juchno J, Haimbaugh C, Bichraoui H, Du Y, Bankston JR, Walker LA,
 Proenza C. 2020. Isoform-specific regulation of HCN4 channels by a family of endoplasmic
 reticulum proteins. *Proc Natl Acad Sci U S A* 117:18079–18090.
 doi:10.1073/pnas.2006238117
 - Porro A, Saponaro A, Gasparri F, Bauer D, Gross C, Pisoni M, Abbandonato G, Hamacher K, Santoro B, Thiel G, Moroni A. 2019. The HCN domain couples voltage gating and cAMP response in hyperpolarization-activated cyclic nucleotide-gated channels. *eLife* **8**:e49672. doi:10.7554/eLife.49672
 - Refisch A, Chung H-Y, Komatsuzaki S, Schumann A, Mühleisen TW, Nöthen MM, Hübner CA, Bär K-J. 2021. A common variation in HCN1 is associated with heart rate variability in schizophrenia. *Schizophr Res* **229**:73–79. doi:10.1016/j.schres.2020.11.017
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector
 E, Voelkerding K, Rehm HL, ACMG Laboratory Quality Assurance Committee. 2015.
 Standards and guidelines for the interpretation of sequence variants: a joint consensus
- recommendation of the American College of Medical Genetics and Genomics and the

Cámara-Checa et al. p.V240M HCN4 and inappropriate sinus tachycardia

```
887
            Association for Molecular Pathology. Genet Med Off J Am Coll Med Genet 17:405-424.
888
            doi:10.1038/gim.2015.30
889
       Rivolta I, Binda A, Masi A, DiFrancesco JC. 2020. Cardiac and neuronal HCN channelopathies.
890
            Pflugers Arch 472:931–951. doi:10.1007/s00424-020-02384-3
891
       Romeo E, Grimaldi N, Sarubbi B, D'Alto M, Santarpia G, Scognamiglio G, Russo MG, Calabrò R.
892
            2011. A pediatric case of cardiomyopathy induced by inappropriate sinus tachycardia:
893
            efficacy of ivabradine. Pediatr Cardiol 32:842-845. doi:10.1007/s00246-011-9964-1
894
       Schweizer PA, Duhme N, Thomas D, Becker R, Zehelein J, Draguhn A, Bruehl C, Katus HA,
895
            Koenen M. 2010. cAMP sensitivity of HCN pacemaker channels determines basal heart
896
            rate but is not critical for autonomic rate control. Circ Arrhythm Electrophysiol 3:542-552.
897
            doi:10.1161/CIRCEP.110.949768
898
       Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. 2005. The FoldX web server: an
899
            online force field. Nucleic Acids Res 33:W382-388. doi:10.1093/nar/gki387
900
       Sheldon RS, Grubb BP, Olshansky B, Shen W-K, Calkins H, Brignole M, Raj SR, Krahn AD, Morillo
901
            CA, Stewart JM, Sutton R, Sandroni P, Friday KJ, Hachul DT, Cohen MI, Lau DH, Mayuga KA,
902
            Moak JP, Sandhu RK, Kanjwal K. 2015a. 2015 heart rhythm society expert consensus
903
            statement on the diagnosis and treatment of postural tachycardia syndrome,
904
            inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm 12:e41-63.
905
            doi:10.1016/j.hrthm.2015.03.029
906
       Sheldon RS, Grubb BP, Olshansky B, Shen W-K, Calkins H, Brignole M, Raj SR, Krahn AD, Morillo
907
            CA, Stewart JM, Sutton R, Sandroni P, Friday KJ, Hachul DT, Cohen MI, Lau DH, Mayuga KA,
908
            Moak JP, Sandhu RK, Kanjwal K. 2015b. 2015 heart rhythm society expert consensus
909
            statement on the diagnosis and treatment of postural tachycardia syndrome,
910
            inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm 12:e41-63.
911
            doi:10.1016/j.hrthm.2015.03.029
912
       Shi W, Wymore R, Yu H, Wu J, Wymore RT, Pan Z, Robinson RB, Dixon JE, McKinnon D, Cohen
913
            IS. 1999. Distribution and prevalence of hyperpolarization-activated cation channel (HCN)
914
            mRNA expression in cardiac tissues. Circ Res 85:e1-6. doi:10.1161/01.res.85.1.e1
915
       Ueda K, Nakamura K, Hayashi T, Inagaki N, Takahashi M, Arimura T, Morita H, Higashiuesato Y,
916
            Hirano Y, Yasunami M, Takishita S, Yamashina A, Ohe T, Sunamori M, Hiraoka M, Kimura
917
            A. 2004. Functional characterization of a trafficking-defective HCN4 mutation, D553N,
918
            associated with cardiac arrhythmia. J Biol Chem 279:27194–27198.
919
            doi:10.1074/jbc.M311953200
920
```

921	Verkerk AO, van Borren MMGJ, Peters RJG, Broekhuis E, Lam KY, Coronel R, de Bakker JMT,
922	Tan HL, Wilders R. 2007. Single cells isolated from human sinoatrial node: action
923	potentials and numerical reconstruction of pacemaker current. Annu Int Conf IEEE Eng
924	Med Biol Soc 2007:904–907. doi:10.1109/IEMBS.2007.4352437
925	Verkerk AO, Wilders R. 2015. Pacemaker activity of the human sinoatrial node: an update on
926	the effects of mutations in HCN4 on the hyperpolarization-activated current. Int J Mol Sci
927	16 :3071–3094. doi:10.3390/ijms16023071
928	Wainger BJ, DeGennaro M, Santoro B, Siegelbaum SA, Tibbs GR. 2001. Molecular mechanism
929	of cAMP modulation of HCN pacemaker channels. Nature 411:805–810.
930	doi:10.1038/35081088
931	Wang Z-J, Blanco I, Hayoz S, Brelidze TI. 2020. The HCN domain is required for HCN channel
932	cell-surface expression and couples voltage- and cAMP-dependent gating mechanisms. J
933	Biol Chem 295 :8164–8173. doi:10.1074/jbc.RA120.013281
934	Winum P-F, Cayla G, Rubini M, Beck L, Messner-Pellenc P. 2009. A case of cardiomyopathy
935	induced by inappropriate sinus tachycardia and cured by ivabradine. Pacing Clin
936	Electrophysiol PACE 32:942–944. doi:10.1111/j.1540-8159.2009.02414.x
937	Yu H, Gall B, Newman M, Hathaway Q, Brundage K, Ammer A, Mathers P, Siderovski D, Hull
938	RW. 2021. Contribution of HCN1 variant to sinus bradycardia: A case report. J Arrhythmia
939	37 :1337–1347. doi:10.1002/joa3.12598

Table 1. Clinical characteristics of the family members studied.

		Age at diagnosis er (year range)	Symptoms	Heart Rate (bpm)		Functional Class (NYHA)		LVEF (%)		Treatment	
Patient	Gender			Baseline	A. T.	Baseline	А. Т.	Baseline	А. Т.	Ivabradine (mg BID)	Bisoprolol
				Mean 24 h	Mean 24 h						(5 mg BID)
					Carrie	ers					
II-1	М	61-65	Yes	95[13]		III	III	23			
III-1	М	36-40	No	100[15]	90[4]*	I	1	45	55	5	+
III-3 (#)	F	31-35	Yes	106[17]	78[5]*	III	1	43	55	5	+
III-7	F	26-30	Yes	101[13]	85[8]*	1-11	1	45	56	5	+
IV-1	F	21-25	No	103[10]	82[19]*	I	ı	51	57	7.5	
IV-4	М	11-15	Yes	111[12]	94[12]*	I	I	60	60	7.5	
IV-5	М	6-10	No	122[15]	101[10]*	I	I	64	64	5	
IV-8	F	11-15	No	112[14]	103[14]*	I	I	60	59	7.5	
IV-9	F	6-10	Yes	117[12]	102[12]*	-	I	63	64	7.5	
					Non car	riers					
II-5	М	56-60		80[15]				55			
III-5	М	41-45		79[13]				56			
III-8	М	41-45		46[14]				56			
III-9	М	41-45		79[11]				55			
IV-2	F	11-15		84[15]				59			
IV-3	М	16-20		75[15]				58			

#: Proband. A.T.: 3 months after initiation of treatment. BID: twice daily. F: female. HR: heart rate. LVEF: left ventricular ejection fraction. M: male. NYHA: New York Heart Association. Mean 24 h HR data are presented as mean[SD]. Student's t-test followed by Pearson correlation tests. *P<0.05 vs baseline.

Tables-source data 1.

Table 2. Resting ECG and cardiac structural parameters of all the family members studied.

Patient				ECG parameters									Chamber characterisation					
	Resting Heart Rate (bpm)		Resting Heart Rate (bpm)		P (ms	5)	PQ (m	ıs)	QRS (r	ns)	QT (m	ıs)	QTc (n	ns)	LVEDD (mm)	LVESD (ı	mm)
	Baseline	A.T.	Baseline	A. T.	Baseline	A. T.	Baseline	A. T.	Baseline	A. T.	Baseline	A. T.	Baseline	A. T.	Baseline	A. T.		
	CARRIERS																	
II-1	117	-	100	-	120	-	96	-	310	-	380	-	53	-	44	-		
III-1	106	73	110	120	140	150	90	90	320	360	390	400	55	56	43	39		
III-3 (#)	107	77	120	120	200	160	80	90	320	360	390	400	53	52	40	40		
III-7	108	83	100	100	160	160	80	100	320	340	390	400	50	53	33	40		
IV-1	102	73	100	100	160	160	80	80	340	360	400	400	46	44	36	31		
IV-4	119	90	80	100	180	200	80	80	310	340	390	410	49	50	33	34		
IV-5	123	100	80	80	140	160	80	90	300	340	380	400	41	40	27	25		
IV-8	123	87	80	100	120	140	80	80	300	340	380	420	45	46	31	30		
IV-9	114	94	120	120	160	166	90	100	320	340	400	420	41	42	26	27		
							NON CAI	RRIERS										
II-5	61	-	100	-	140	-	90	-	380	-	380	-	48	-	34	-		
III-5	75	-	100	-	180	-	80	-	340	-	380	-	50	-	34	-		
III-8	81	-	100	-	160	-	90	-	360	-	400	-	52	-	40	-		
III-9	80	-	80	-	140	-	80	-	340	-	410	-	50	-	34	-		
IV-2	82	-	80	-	120	-	80	-	360	-	410	_	43	-	30	-		
IV-3	53	-	100	-	160	-	90	-	400	-	420	-	50,2	-	34,8	-		

A.T.: 3 months after treatment. bpm: beats per minute. ECG: electrocardiogram. F: female. HR: heart rate. LVEDD: left ventricular end-diastolic diameter. LVEF: left ventricular ejection fraction. LVESD: left ventricular end-systolic diameter. QT values were corrected using the Bazzet's and Fredericia's formulas in subjects with HR <100 and ≥100 bpm, respectively. Statistical comparison between baseline measurements and data after treatment was analyzed by paired Student t-tests.

Tables-source data 1.

Table 3. Summary of all nonsynonymous variants identified in the proband.

Gene	Genotype	Ancestral allele /Variant	dbSNP_ID	MAF	Aminoacid substitution	Transcript	Provean prediction	SIFT Prediction	Polyphen- 2 Prediction	Mutation Taster	CADD Score
CXADR	HET	C/G	-	-	L227V	NM_001338.5	Neutral	Tolerated	Benign	Disease causing	13.8
HCN4	HET	G/A	rs1207487211	0.000003982	V240M	NM_005477.3	Neutral	Deleterious	Probably damaging	Disease causing	28.9
LDB3	HET	-	-	-	P441_S448del	NM_007078.2	-	-	-	-	-

CADD= Combined Annotation Dependent Depletion (A score greater of equal 20 indicates that it is predicted to be the 1% most deleterious substitutions that you can do to the human genome); HET= heterozygous; MAF= mean minor allele frequency from all ethnic groups where the variant has been identified as provided in https://gnomad.broadinstitute.org/; SIFT= Sorting Intolerant From Tolerant.

Table 4. Effects of p.V240M variant on the time- and voltage-dependent properties of macroscopic and unitary HCN4 currents

			Whole-ce	II			
HCN4	E _{rev} (mV)	Vh _{act} (mV)	K act	$\Delta I_{NS}/I_{SS}$	τ _{deact} (s)	I _{HCN4} density -160 mV (pA/pF)	I _{HCN4} density -60 mV (pA/pF)
WT	-6.0±1.9	-131.3±2.5	11.5±0.7	0.62±0.07	0.9±0.2	-43.1±4.7	-1.2±0.2
p.V240M	-6.8±2.3	-111.7±2.6*	12.3±0.7	0.79±0.03*	2.1±0.4*	-128.5±21.2*	-8.6±2.6*
WT+p.V240M	-6.5±1.6	-120.1±2.7*#	13.0±1.0	0.68±0.06	1.4±0.2	-72.9±8.3*#	4.3±1.5*#
			Single-chan	nel			
HCN4	τ _{ορεΝ} (ms)§	τ _{CLOSED} (ms)§	MOT (ms)	f _o (Hz)	Po	<i>i</i> _{HCN4} −90 mV (pA)	γ (pS)
WT	17.3	68.1	36.2±9.8	5.2±1.1	0.11±0.02	-1.6±0.3	16.3±2.7
p.V240M	9.3*	18.6*	17.1±3.5*	13.2±1.0*	0.23±0.03*	-2.9±0.4*	39.8±4.2*

 $\Delta I_{NS}/I_{SS}$ ratio between the instantaneous current (I_{INS}) and the steady-state current (I_{SS}) generated by the pulse protocol used to determine the deactivation kinetics after 1-s interval at -40 mV between the two test pulses to -120 mV. MOT= mean open time. P_0 = open probability. τ_{OPEN} = open time constant yielded by the fit of a monoexponential function to the open time histogram. τ_{CLOSED} = closed time constant yielded by the fit of a monoexponential function to the closed time histogram. Each value represents mean±SEM of >5 cells/experiments (biological replicates) from at least 3 different dishes in each group. Statistical comparisons were made by using ANOVA followed by Tukey's test (Whole-cell) or using *t*-test (single-channel). *P<0.05 vs WT; #P<0.05 vs p.V240M. §These values are obtained by the fit of a monoexponential fit to the curves constructed with the respective mean values

Table 5. Characteristics of the AP generated by a mathematical model of the human sinoatrial node action potential

Parameter	WT	p.V240M	WT+p.V240M
Cycle Length (ms)	814	410	555
Frequency (Hz/bpm)	1.23/73.8	2.44/146.3	1.80/108.1
Diastolic depolarization rate (mV/s)	48.1	126.7	76.7
Mean Diastolic Potential (mV)	-58.9	- 57.5	-58
Action potential amplitude (mV)	85.3	81.5	84.0
Overshoot (mV)	26.4	24.0	26.0
APD ₂₀ (ms)	98.5	85.0	93.2
APD ₅₀ (ms)	136	122.9	129.6
APD ₉₀ (ms)	161.5	148.7	155.0

APD₂₀, APD₅₀, APD₉₀= action potential duration measured at 20%, 50% and 90% of repolarization; bpm= beats per minute.